Published online before print December 15, 2005, doi: 10.1161/01.RES.0000200181.59551.71
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 American Heart Association, Inc.
Integrative Physiology |
Xanthine Oxidoreductase Inhibition Causes Reverse Remodeling in Rats With Dilated Cardiomyopathy
From the Department of Medicine, Cardiology Division and Institute for Cell Engineering (K.M.M., R.M.S., K.H.S., S.L., M.Z., A.P.S., C.E.B., K.M.V., J.M.H.), and Department of Anesthesiology and Critical Care Medicine (D.L.), Johns Hopkins Medical Institutions, Baltimore, Md; and Department of Medicine (R.M.S.), Cardiology Division, Federal University of Sao Paulo, Brazil.
Correspondence to Joshua M. Hare, MD, The Johns Hopkins Medical Institutions, Cardiology Division, 733 Rutland Ave, Broadway Research Building 659, Baltimore, MD 21212. E-mail jhare{at}mail.jhmi.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Increased reactive oxygen species (ROS) generation is implicated in cardiac remodeling in heart failure (HF). As xanthine oxidoreductase (XOR) is 1 of the major sources of ROS, we tested whether XOR inhibition could improve cardiac performance and induce reverse remodeling in a model of established HF, the spontaneously hypertensive/HF (SHHF) rat. We randomized Wistar Kyoto (WKY, controls, 18 to 21 months) and SHHF (19 to 21 months) rats to oxypurinol (1 mmol/L; n=4 and n=15, respectively) or placebo (n=3 and n=10, respectively) orally for 4 weeks. At baseline, SHHF rats had decreased fractional shortening (FS) (31±3% versus 67±3% in WKY, P<0.0001) and increased left-ventricular (LV) end-diastolic dimension (9.7±0.2 mm versus 7.0±0.4 mm in WKY, P<0.0001). Whereas placebo and oxypurinol did not change cardiac architecture in WKY, oxypurinol attenuated decreased FS and elevated LV end-diastolic dimension, LV end-systolic dimension, and LV mass in SHHF. Increased myocyte width in SHHF was reduced by oxypurinol. Additionally, fetal gene activation, altered calcium cycling proteins, and upregulated phospho–extracellular signal–regulated kinase were restored toward normal by oxypurinol (P<0.05 versus placebo-SHHF). Importantly, SHHF rats exhibited increased XOR mRNA expression and activity, and oxypurinol treatment reduced XOR activity and superoxide production toward normal, but not expression. On the other hand, NADPH oxidase activity remained unchanged, despite elevated subunit protein abundance in treated and untreated SHHF rats. Together these data demonstrate that chronic XOR inhibition restores cardiac structure and function and offsets alterations in fetal gene expression/Ca2+ handling pathways, supporting the idea that inhibiting XOR-derived oxidative stress substantially improves the HF phenotype.
Key Words: xanthine oxidoreductase • remodeling • gene expression • heart failure
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Emerging data implicates oxidative stress (OS) in heart failure (HF) pathophysiology, contributing to cardiac remodeling,1,2 mechanoenergetic uncoupling,3,4 and depressed myofilament calcium sensitivity.5,6 The major enzymatic sources of reactive oxygen species (ROS) in HF are xanthine oxidoreductase (XOR)7 and nicotinamide adenine dinucleotide 2'-phosphate (NADPH) oxidase.8 Several studies demonstrate XOR upregulation in animal models4–7,9,10 and in human dilated cardiomyopathy.3,11 Functionally, XOR inhibition (XOI) acutely enhances myocardial mechanical efficiency in both animals and humans with HF.3,4 However, whereas NADPH oxidase is implicated in
1-adrenoreceptor stimulated hypertrophic signaling12 and contributes to OS in reperfused hearts, playing a major role in post–myocardial infarction (MI) microvascular obstruction ("no-reflow" phenomenon)13 and, like XOR, is increased in human HF,8 the relative contribution of XOR and NADPH oxidase to HF pathophysiology requires further clarification. A recent series of studies has begun to examine the role of XOR in the cardiac remodeling process.2,6,14 These data contribute to the growing argument implicating XOR as a key source of ROS in evolving HF. Whether inhibition of XOR can elicit reverse remodeling in established dilated cardiomyopathy remains unknown.
Here we tested the hypothesis that cardiac XOR adversely affects cardiac remodeling in established cardiomyopathy in spontaneously hypertensive/HF (SHHF) rats. We show that chronic XOI reverses maladaptive cardiac remodeling through effects on cardiac structure, function, and fetal gene activation in SHHF rats, and that this process occurs independently of NADPH oxidase.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
An expanded Materials and Methods section is available in the online data supplement at http://circres.ahajournals.org.
Animals and Experimental Protocol
We studied SHHF (n=25) rats and their controls, Wistar Kyoto (WKY, n=8) rats (Charles River Laboratories Inc, Wilmington, Mass). The SHHF rat is a dilated cardiomyopathy model with hypertension progressing to HF.15 This model shares common phenotypic features with human HF,15–17 including activated fetal gene program18 and elevated XOR activity.5 We treated both SHHF and WKY rats with the XOR inhibitor oxypurinol.19 SHHF and WKY rats were randomly assigned to placebo or treatment with oxypurinol for 4 weeks. Echocardiographic measurements were taken at baseline, 2 weeks, and at the end of the study. In vivo assessment of left-ventricular (LV) hemodynamics was performed at the end of treatment and animals were euthanized. The Institutional Animal Care and Use Committee of The Johns Hopkins University School of Medicine approved all protocols and experimental procedures.
Echocardiographic Measurements
Echocardiographic assessments were performed in WKY and SHHF anesthetized (1% to 2% isoflurane inhalation) rats using a Sonos 5500 Echocardiogram (Philips, Andover, Mass) equipped with a 15-MHz linear transducer. LV anterior wall thickness (AWT), posterior wall thickness (PWT), and end-diastolic (LVEDd) and end-systolic (LVESd) diameters were recorded from M-mode images using averaged measurements from 3 to 5 consecutive cardiac cycles.
LV Hemodynamics
Rats were anesthetized by intraperitoneal injection of ketamine (50 mg/kg) and acepromazine (2 mg/kg). A 2-F micromanometer tipped catheter (SPR-838, Millar Instruments, Houston, Tex) was inserted into the right carotid artery and retrogradely advanced into the left ventricle.
Histopathology
Excised hearts were processed using routine histological procedures. Five-micrometer sections were sliced and stained with hematoxylin/eosin (H&E). Myocyte width was measured at the level of the nucleus in longitudinally sectioned myocytes. All measurements were determined using NIH Image version 1.30v for Windows.
Measurement of mRNA Expression by Quantitative PCR
Fluorescence based real time quantitative PCR (qPCR) was used to determine the mRNA expression of the following genes: XOR, atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), -myosin heavy chain (-MHC), ß-MHC, and -skeletal actin (-SA).
Measurement of XOR Activity
XOR activity was measured using the horseradish peroxidase-linked Amplex Red fluorescence assay (Molecular Probes, Invitrogen Detection Technologies), as described previously.20
Oxidative Fluorescent Microtopography Using the Fluorescent Dihydroethidium Probe
Fresh, unfixed heart segments from WKY, WKY+oxypurinol, SHHF, and SHHF+oxypurinol rats were frozen and oxidative fluorescent microtopography was performed using the fluorescent dihydroethidium (DHE) probe, as described previously.21
GSH/GSSG Ratio
Determination of the reduced glutathione/glutathione disulfide (GSH/GSSG) ratio was performed by using the glutathione assay kit (Cayman chemical, Ann Arbor, Mich).
Measurement of NADPH Oxidase Activity
NADPH-dependent superoxide (O2·–) production was measured in LV homogenates (mentioned in XOR activity) using lucigenin-enhanced chemiluminescence (ß-NADPH 300 µmol/L; at room temperature) on a microplate luminometer (Veritas, Turner Biosystems, Sunnyvale, Calif).
Western Blotting
Whole heart proteins were prepared and Western blots analysis was performed as described.22 The blots were incubated with primary anti-p47phox antibody, anti-p22phox antibody, anti-p67phox antibody, anti-gp91phox antibody, anti–sarcoplasmic reticulum Ca+2 ATPase (SERCA2a) antibody, anti–Na+/Ca+2 exchanger (NCX) antibody, anti-phospholamban (PLB) antibody, anti–extracellular signal-regulated kinase (ERK) antibody, or anti-pERK antibody.
Statistical Analysis
Data are reported as mean±SEM. Statistical significance was determined by 1-way or 2-way ANOVA where appropriate, followed by Student–Newman–Keuls post hoc analysis (GraphPad, Instat, and STATA statistical software). The null hypothesis was rejected at P<0.05.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Reverse LV Remodeling
Baseline echocardiography revealed that SHHF rats were characterized by decreased FS, with increased LV mass (LVM) and LV internal diameters, as compared with aged matched WKY controls (Table 1). The higher LVM present in SHHF rats was attributable to both increased LVEDd and AWT in comparison to WKY controls (Table 1).
|
At the end of 4 weeks of oxypurinol treatment, SHHF treated rats had improved FS (45±7% versus 27±5% in untreated SHHF, P<0.01), smaller LVEDd (9.7±0.7 mm versus 11.6±0.4 mm in untreated SHHF, P<0.01) and LVESd (5.6±0.9 mm versus 8.5±0.3 mm in untreated SHHF, P<0.01), and lower LVM (1790±217 mg versus 2731±225 mg in untreated SHHF, P<0.01) as compared with untreated SHHF rats (Figure 1A through 1D). Placebo-treated SHHF rats displayed progressive increases in LVEDd, LVESd, and LVM, with decreased FS. Echocardiographic parameters remained unchanged throughout the period of treatment (placebo or oxypurinol) in WKY.
|
, n=3), WKY+oxypurinol (WKY+O; 
, n=4), SHHF+placebo (SHHF+P; 
, n=10), and SHHF+oxypurinol (SHHF+O; 
, n=15). A, LV FS is significantly decreased in SHHF rats as compared with WKY but is restored by oxypurinol. LVEDd (B), LVESd (C), and LVM (D) are significantly increased in SHHF rats as compared with WKY. In SHHF, oxypurinol treatment attenuates the increase in all of these parameters. *P<0.01 vs WKY+P and WKY+O at baseline (0 weeks) and at the end of the study (4 weeks) by 2-way ANOVA; 
P<0.01 vs SHHF+P by interaction term (2-way ANOVA); 
P<0.05 by repeated measure within groups. E, Representative LV pressure–volume loops obtained by transient inferior vena cava occlusion in SHHF+P and SHHF+O rats demonstrates that oxypurinol treatment leads to decreased LV volume and increased Ees in SHHF rats.In vivo hemodynamic analysis revealed increased LV volumes in untreated SHHF rats (P<0.05) in comparison to WKY that regressed toward normal after 4 weeks of oxypurinol treatment (Table 2). Ejection fraction was smaller (P<0.05) in untreated SHHF rats than in WKY and treated SHHF rats. Oxypurinol induced an increase in the slope of the end-systolic pressure-volume relation (Ees) (P=0.01; Table 2 and Figure 1E). There was no significant difference in LV end-systolic pressure or LV end-diastolic pressure across the groups (Table 2).
|
Reverse remodeling was demonstrated at the histological level as oxypurinol treatment regressed the cellular hypertrophy in SHHF rats. The cell width of cardiac myocytes from SHHF untreated rats (10.8±0.3 µm, n=35 cells, P<0.05) was higher than in both treated (9.8±0.2 µm, n=39) and untreated (9.4±0.2 µm, n=39) WKY rats. Oxypurinol treatment led to a significant regression in cardiac myocytes width in SHHF rats (9.8±0.2 µm, n=34, P<0.05) as compared with untreated SHHF rats (Figure 2). Additionally, the mitogen-activated protein kinase pathway was studied by determining the protein abundance of total and phosphorylated ERK. The pERK/ERK ratio was upregulated in SHHF rats and restored toward normal in the oxypurinol-treated group (Figure 3).
|
|
Ca2+ Cycling Proteins
The depressed cardiac performance in SHHF rats was associated with changes in Ca2+ handling proteins. SERCA2a was downregulated (–0.68-fold), NCX (1.36-fold) was upregulated, and PLB (data not shown) was unchanged in SHHF relative to WKY untreated controls. In oxypurinol-treated SHHF rats, NCX was restored toward normal, whereas SERCA2a had partial restoration (Figure 3).
Fetal Gene Program Activity
Hypertrophied and failing hearts are characterized by altered expression of the prototypical members of the fetal gene program.23 We confirmed upregulated expression of ANP (7.3-fold, P<0.001), BNP (1.7-fold, P<0.01), ß-MHC (2.4-fold, P<0.01), and -SA (3.7-fold, P<0.001), with downregulation of -MHC (4.4-fold, P<0.01), in the left ventricle of SHHF rats18 as compared with WKY (Figure 4). Oxypurinol treatment offset the changes in expression of these genes in SHHF rats, with a complete restoration being achieved for BNP and ß-MHC. Oxypurinol did not change the expression of any of these genes in WKY rats (Figure 4).
|
Oxidative Stress
ROS production was higher in SHHF rats compared with WKY subgroups and oxypurinol treatment restored it toward normal. Oxidative fluorescent microtopography using the fluorescent probe DHE (orange staining), demonstrated elevated O2·– production in SHHF cardiac myocytes as compared with controls (Figure 5A). Oxypurinol treatment reduced O2·– production in SHHF, while having no effect in controls (Figure 5A). The increase in OS in SHHF rats was further characterized by the decrease in GSH/GSSG ratio (P<0.05; Figure 5B), an index of intracellular OS, in relation to controls. Oxypurinol treatment restored GSH/GSSG ratio in SHHF toward normal, demonstrating reduction in ROS production.
|
Myocardial XOR Expression and Activity
XOR mRNA was upregulated in SHHF compared with WKY, and oxypurinol treatment did not affect XOR gene expression (Figure 5C). This increased expression translated into increased XOR activity in SHHF (54.9±4.1 mU/µg) as compared with WKY (37.2±1.5 mU/µg, P<0.05; Figure 5D). Oxypurinol treatment reduced XOR activity in SHHF toward normal (SHHF+oxypurinol 35.7±3.7 mU/µg, P<0.05 versus SHHF and P=NS versus WKY) but did not affect XOR activity in WKY (WKY+oxypurinol 35.8±2.4 mU/µg, P=NS versus WKY).
NADPH Oxidase Activity and Protein Abundance
We measured NADPH oxidase activity to determine the relative contribution of NADPH oxidase to the increased O2·– production in SHHF rats. NADPH oxidase activity was not increased in SHHF relative to WKY rats (63.22±8.01 light units/mg · min–1 in SHHF versus 56.23±10.44 light units/mg · min–1 in WKY rats, P=NS; Figure 6A), and oxypurinol did not affect this activity in either group (52.40±4.70 light units/mg · min–1 in WKY+oxypurinol and 59.18±7.98 light units/mg · min–1 in SHHF+oxypurinol, P=NS; Figure 6A). NADPH oxidase activity was inhibited by diphenyleneiodonium (DPI), but not by allopurinol or N
-nitro-L-arginine methyl ester hydrochloride (L-NAME) in all 4 groups (Figure 6A). Interestingly, despite unchanged NADPH activity, cardiac protein abundance of NADPH oxidase subunits (Gp91phox and P67phox) were elevated in SHHF rats in relation to WKY, whereas P22phox and P47phox were unchanged (Figure 6B). Oxypurinol did not affect the abundance of these subunits.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The major findings of this study are that chronic XOI with accompanying reductions in OS favorably affects the natural history of HF, inducing reverse remodeling with restoration of cardiac structure and function while changing the altered patterns of Ca2+ cycling proteins and reversing alterations in gene expression in an established model of genetic cardiomyopathy. The beneficial effect of oxypurinol treatment was not secondary to a reduction in afterload between SHHF groups. Furthermore, SHHF rats exhibited increased XOR mRNA expression and activity but unchanged NADPH oxidase activity, and with oxypurinol treatment, XOR activity and O2·– production, but not expression, were reduced toward normal, whereas NADPH oxidase activity was unaltered, suggesting the improved HF phenotype was attributable to reduction in XOR-mediated OS.
There is accumulating data supporting a role for OS in HF, and previous studies have used ischemic2,6 or pacing-induced HF4,9,14 models to demonstrate the importance of OS in HF. In addition to the development of cardiac hypertrophy23,24 and post-MI remodeling,2 OS has been linked to abnormal excitation–contraction coupling,25,26 myocyte apoptosis,27,28 and ß-adrenergic downregulation.9 Recent studies in post-MI models2,6,29 and in a troponin I–truncated mouse model30 have reported that XOI attenuates LV remodeling and dysfunction,29,30 reducing myocardial hypertrophy and interstitial fibrosis,2 while improving excitation–contraction coupling, cardiac contractility, ß-adrenergic regulation, and survival.6,31 Additionally, using a canine model, our group recently reported improved contractility, reduced systemic vasoconstriction, and improved ventricular vascular coupling, but unaltered preload, by chronic XOI.14 In the SHHF rats, oxypurinol also resulted in improved contractility, but, unlike in the pacing dog model,14 LV volumes were reduced. This difference is likely attributable to differences in the models and the fact that the stimulus for cardiac injury was given in an ongoing basis in the previous canine study. Whether XOI can reverse established LV dysfunction in nonischemic dilated cardiomyopathy had heretofore remained unknown. Our observation of substantial reverse remodeling, resulting in better cardiac performance and architecture in treated versus untreated animals, offers unique insights into the mechanisms underlying hypertrophy and HF pathophysiology. Notably, the SHHF rat is a hypertensive model that evolves into a phase of frank LV dysfunction15 and exhibits symptoms and biochemical changes that parallel those observed in patients with cardiomyopathy and congestive HF.15,18
The pattern of NCX upregulation and SERCA2a downregulation observed in SHHF rats is also present in other HF experimental models32–34 and in human HF.35–37 Unchanged PLB expression in SHHF is also observed in other HF models, such as post-MI38 and in human HF.39–41 Oxypurinol restored NCX protein abundance toward normal and partially restored SERCA2a expression. Reduced SERCA2a protein abundance with partial restoration after treatment correlates with depressed systolic cardiac performance in SHHF rats that improves with oxypurinol treatment. The reduced SERCA2a protein abundance could contribute to diastolic dysfunction, but the concomitant increase in NCX likely contributes to improved diastolic Ca2+ removal, as the relaxation time constant (
) in SHHF rats was close to controls (Table 2).
XOI is previously shown to improve myocardial energetics.3,4,7,42 In this regard, HF is associated with decrease of total creatine pool, [pCr], [pCr]/[ATP] ratio, and myocardial total creatine kinase (CK) activity and a fetal shift in CK isoform expression,43–45 and HF treatment is accompanied by increase in total CK activity and partially restoration of CK isoform expression.44,45 Furthermore, XOR reduces CK activity in vitro, and this effect is reversed by superoxide dismutase46 and XOI improve ventricular function while normalizing high-energy phosphate ratio in post-MI–induced HF in mice.42 Therefore, it is possible that improvement in myocardial energetics may be one of the mechanisms for XOI beneficial effects in SHHF rats.
Furthermore, our findings are in line with the known activation of the fetal gene program that occurs in HF.18,23 This program consists of a constellation of myocardial genes switched off shortly after birth but selectively reactivated in response to chronic hemodynamic overload, including ANP, BNP, -MHC, ß-MHC, and -SA.47 Recent studies using gene therapy approaches targeting calcium cycling genes to alter protein transcription in failing hearts have shown promising results.26,48 However, this is the first study investigating the effects of XOI on OS in HF which demonstrates that administration of an orally active compound has effects on gene transcription preventing adverse remodeling while preserving cardiac function in genetically programmed cardiomyopathy. The influence of XOI on the fetal gene program is noteworthy and suggests a direct effect of ROS on the transcription of these genes, as angiotensin-converting enzyme inhibitors and aldosterone antagonists, which also attenuate the progression of myocardial remodeling in SHHF rats,49 do so without having the transcriptional effects we observed with XOI.
Finally, we evaluated the relative role of XOR and NADPH oxidase in OS in HF. Recently discovered interactions between NADPH oxidase and XOR delineate crosstalk regarding ROS generation. NADPH oxidase may maintain endothelial XOR levels, playing a critical role in the conversion of xanthine dehydrogenase to XOR.50 Also, mice deficient in gp91phox, continue to exhibit NADPH-dependent O2·– generation and develop pressure overload–induced hypertrophy, suggesting alternative sources of ROS generation.51 Our findings demonstrate that XOR is an important source of ROS generation in HF, with probably a more relevant role than NADPH oxidase, a contention supported by our physiological observations with regard to increased XOR activity and O2·– production, and unaffected NADPH activity in SHHF rats, despite increased NADPH oxidase subunit abundance. This hypothesis is further supported by the profound effects of XOI on reverse remodeling, Ca2+ cycling protein abundance and fetal gene activation in rat myocardium, which occur with concomitant decreased XOR activity but maintained NADPH oxidase activity. However, the fact that we have not tested a NADPH oxidase inhibitor in vivo limits our conclusion.
The limitations of the present work include the fact that the LV diameters, mass, and FS measured by echocardiography did not reduce beyond baseline levels in SHHF treated animals. LV remodeling persisted in untreated animals but was halted in treated animals according to echocardiographic parameters. However, the observations that XOI-treated SHHF rats had LV volumes measured by conductance catheter and myocyte size similar to WKY controls does support a reverse remodeling effect. Additionally, it remains unclear whether the changes in either the activation of the fetal gene program or calcium cycling protein abundance preceded changes in LV structure and function.
In summary, we have demonstrated that chronic XOI with oxypurinol causes reverse LV remodeling, improves function, alters Ca2+ cycling protein abundance, and restores molecular markers of the fetal gene program toward normal in SHHF rats. Furthermore, we show that improved HF phenotype is attributable to XOR-mediated reduced OS and that the contribution of NADPH oxidase is relatively minimal. These data support the idea that that XOR is a primary source of ROS generation in failing hearts and that its upregulation contributes to maladaptive cardiac hypertrophy, directly participating in the progression of LV failure.
|
Acknowledgments |
|---|
This work was supported by the Donald W. Reynolds Foundation and NIH grants RO1 HL-65455 and RO1 AG-025017 (to J.M.H.).
|
Footnotes |
|---|
This manuscript was sent to Joseph Loscalzo, Consulting Editor, for review by expert referees, editorial decision, and final disposition.
J.M.H. is a paid consultant for Cardiome Pharma Corp. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.
*Both authors contributed equally to this study. 
Original received July 24, 2005; revision received November 3, 2005; accepted December 5, 2005.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Kinugawa S, Tsutsui H, Hayashidani S, Ide T, Suematsu N, Satoh S, Utsumi H, Takeshita A. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ Res. 2000; 87: 392–398.
2. Engberding N, Spiekermann S, Schaefer A, Heineke A, Wiencke A, Muller M, Fuchs M, Hilfiker-Kleiner D, Hornig B, Drexler H, Landmesser U. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation. 2004; 110: 2175–2179.
3. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, Marban E, Hare JM. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001; 104: 2407–2411.
4. Ekelund UE, Harrison RW, Shokek O, Thakkar RN, Tunin RS, Senzaki H, Kass DA, Marban E, Hare JM. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res. 1999; 85: 437–445.
5. Kogler H, Fraser H, McCune S, Altschuld R, Marban E. Disproportionate enhancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing rat myocardium. Cardiovasc Res. 2003; 59: 582–592.[CrossRef][Medline] [Order article via Infotrieve]
6. Stull LB, Leppo MK, Szweda L, Gao WD, Marban E. Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res. 2004; 95: 1005–1011.
7. Saavedra WF, Paolocci N, St John ME, Skaf MW, Stewart GC, Xie JS, Harrison RW, Zeichner J, Mudrick D, Marban E, Kass DA, Hare JM. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res. 2002; 90: 297–304.
8. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, Shah AM. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol. 2003; 41: 2164–2171.
9. Ukai T, Cheng CP, Tachibana H, Igawa A, Zhang ZS, Cheng HJ, Little WC. Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure. Circulation. 2001; 103: 750–755.
10. de Jong JW, Schoemaker RG, de Jonge R, Bernocchi P, Keijzer E, Harrison R, Sharma HS, Ceconi C. Enhanced expression and activity of xanthine oxidoreductase in the failing heart. J Mol Cell Cardiol. 2000; 32: 2083–2089.[CrossRef][Medline] [Order article via Infotrieve]
11. Landmesser U, Spiekermann S, Dikalov S, Tatge H, Wilke R, Kohler C, Harrison DG, Hornig B, Drexler H. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation. 2002; 106: 3073–3078.
12. Xiao L, Pimentel DR, Wang J, Singh K, Colucci WS, Sawyer DB. Role of reactive oxygen species and NAD(P)H oxidase in alpha(1)-adrenoceptor signaling in adult rat cardiac myocytes. Am J Physiol Cell Physiol. 2002; 282: C926–C934.
13. Duilio C, Ambrosio G, Kuppusamy P, DiPaula A, Becker LC, Zweier JL. Neutrophils are primary source of O2 radicals during reperfusion after prolonged myocardial ischemia. Am J Physiol Heart Circ Physiol. 2001; 280: H2649–H2657.
14. Amado LC, Saliaris AP, Raju SV, Lehrke S, St John M, Xie J, Stewart G, Fitton T, Minhas KM, Brawn J, Hare JM. Xanthine oxidase inhibition ameliorates cardiovascular dysfunction in dogs with pacing-induced heart failure. J Mol Cell Cardiol. 2005; 39: 531–536.[CrossRef][Medline] [Order article via Infotrieve]
15. McCune SA, Baker PB, Stills HF Jr. SHHF/Mcc-cp rat: model of obesity, noninsulin-dependent diabetes, and congestive heart failure. Ilar News. 1990; 32: 23–27.
16. Bergman MR, Kao RH, McCune SA, Holycross BJ. Myocardial tumor necrosis factor-alpha secretion in hypertensive and heart failure-prone rats. Am J Physiol. 1999; 277: H543–H550.[Medline] [Order article via Infotrieve]
17. Holycross BJ, Summers BM, Dunn RB, McCune SA. Plasma renin activity in heart failure-prone SHHF/Mcc-facp rats. Am J Physiol. 1997; 273: H228–H233.[Medline] [Order article via Infotrieve]
18. Heyen JR, Blasi ER, Nikula K, Rocha R, Daust HA, Frierdich G, Van Vleet JF, De Ciechi P, McMahon EG, Rudolph AE. Structural, functional, and molecular characterization of the SHHF model of heart failure. Am J Physiol Heart Circ Physiol. 2002; 283: H1775–H1784.
19. Earll JM, Saavedra M. Oxipurinol therapy in allopurinol-allergic patients. Am Fam Physician. 1983; 28: 147–148.[Medline] [Order article via Infotrieve]
20. Mohanty JG, Jaffe JS, Schulman ES, Raible DG. A highly sensitive fluorescent micro-assay of H2O2 release from activated human leukocytes using a dihydroxyphenoxazine derivative. J Immunol Methods. 1997; 202: 133–141.[CrossRef][Medline] [Order article via Infotrieve]
21. Khan SA, Lee K, Minhas KM, Gonzalez DR, Raju SV, Tejani AD, Li D, Berkowitz DE, Hare JM. Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling. Proc Natl Acad Sci U S A. 2004; 101: 15944–15948.
22. Khan SA, Skaf MW, Harrison RW, Lee K, Minhas KM, Kumar A, Fradley M, Shoukas AA, Berkowitz DE, Hare JM. Nitric oxide regulation of myocardial contractility and calcium cycling: independent impact of neuronal and endothelial nitric oxide synthases. Circ Res. 2003; 92: 1322–1329.
23. Dorn GW, Robbins J, Sugden PH. Phenotyping hypertrophy: eschew obfuscation. Circ Res. 2003; 92: 1171–1175.
24. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol. 2002; 34: 379–388.[CrossRef][Medline] [Order article via Infotrieve]
25. Perez NG, Hashimoto K, McCune S, Altschuld RA, Marban E. Origin of contractile dysfunction in heart failure: calcium cycling versus myofilaments. Circulation. 1999; 99: 1077–1083.
26. del Monte F, Hajjar RJ. Targeting calcium cycling proteins in heart failure through gene transfer. J Physiol. 2003; 546: 49–61.
27. Hayakawa Y, Chandra M, Miao W, Shirani J, Brown JH, Dorn GW, Armstrong RC, Kitsis RN. Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Galpha(q) transgenic mice. Circulation. 2003; 108: 3036–3041.
28. Hare JM. Oxidative stress and apoptosis in heart failure progression. Circ Res. 2001; 89: 198–200.
29. Mellin V, Isabelle M, Oudot A, Vergely-Vandriesse C, Monteil C, Di Meglio B, Henry JP, Dautreaux B, Rochette L, Thuillez C, Mulder P. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J. 2005; 26: 1544–1550.
30. Duncan JG, Ravi R, Stull LB, Murphy AM. Chronic xanthine oxidase inhibition prevents myofibrillar protein oxidation and preserves cardiac function in a transgenic mouse model of cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005; 289: H1512–H1518.
31. Perez NG, Gao WD, Marban E. Novel myofilament Ca2+-sensitizing property of xanthine oxidase inhibitors. Circ Res. 1998; 83: 423–430.
32. Mishra S, Sabbah HN, Rastogi S, Imai M, Gupta RC. Reduced sarcoplasmic reticulum Ca2+ uptake and increased Na+-Ca2+ exchanger expression in left ventricle myocardium of dogs with progression of heart failure. Heart Vessels. 2005; 20: 23–32.[CrossRef][Medline] [Order article via Infotrieve]
33. Wang LC, Ma H, He JG, Liao XX, Chen WF, Leng XY, Ma L, Mai WY, Tao J, Zeng WT, Liu J, Dong YG, Tang AL, Feng C. Effect of angiotensin converting enzyme inhibitor on the calcium transients and calcium handling proteins in ventricular myocytes from rats with heart failure. Chin Med J (Engl). 2005; 118: 731–737.[Medline] [Order article via Infotrieve]
34. Lu L, Mei DF, Gu AG, Wang S, Lentzner B, Gutstein DE, Zwas D, Homma S, Yi GH, Wang J. Exercise training normalizes altered calcium-handling proteins during development of heart failure. J Appl Physiol. 2002; 92: 1524–1530.
35. Studer R, Reinecke H, Bilger J, Eschenhagen T, Bohm M, Hasenfuss G, Just H, Holtz J, Drexler H. Gene expression of the cardiac Na(+)-Ca2+ exchanger in end-stage human heart failure. Circ Res. 1994; 75: 443–453.
36. Hasenfuss G, Meyer M, Schillinger W, Preuss M, Pieske B, Just H. Calcium handling proteins in the failing human heart. Basic Res Cardiol. 1997; 92 (suppl 1): 87–93.[CrossRef][Medline] [Order article via Infotrieve]
37. Lehnart SE, Schillinger W, Pieske B, Prestle J, Just H, Hasenfuss G. Sarcoplasmic reticulum proteins in heart failure. Ann N Y Acad Sci. 1998; 853: 220–230.[CrossRef][Medline] [Order article via Infotrieve]
38. Yue P, Long CS, Austin R, Chang KC, Simpson PC, Massie BM. Post-infarction heart failure in the rat is associated with distinct alterations in cardiac myocyte molecular phenotype. J Mol Cell Cardiol. 1998; 30: 1615–1630.[CrossRef][Medline] [Order article via Infotrieve]
39. Jiang MT, Lokuta AJ, Farrell EF, Wolff MR, Haworth RA, Valdivia HH. Abnormal Ca2+ release, but normal ryanodine receptors, in canine and human heart failure. Circ Res. 2002; 91: 1015–1022.
40. El Armouche A, Pamminger T, Ditz D, Zolk O, Eschenhagen T. Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts. Cardiovasc Res. 2004; 61: 87–93.
41. Kubo H, Margulies KB, Piacentino V, III, Gaughan JP, Houser SR. Patients with end-stage congestive heart failure treated with beta-adrenergic receptor antagonists have improved ventricular myocyte calcium regulatory protein abundance. Circulation. 2001; 104: 1012–1018.
42. Naumova AV, Chacko VP, Ouwerkerk R, Stull L, Marban E, Weiss RG. Xanthine oxidase inhibitors improve energetics and function following infarction in the failing mouse heart. Am J Physiol Heart Circ Physiol. In press.
43. Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res. 2004; 95: 135–145.
44. Park SJ, Zhang J, Ye Y, Ormaza S, Liang P, Bank AJ, Miller LW, Bache RJ. Myocardial creatine kinase expression after left ventricular assist device support. J Am Coll Cardiol. 2002; 39: 1773–1779.
45. Shen W, Spindler M, Higgins MA, Jin N, Gill RM, Bloem LJ, Ryan TP, Ingwall JS. The fall in creatine levels and creatine kinase isozyme changes in the failing heart are reversible: complex post-transcriptional regulation of the components of the CK system. J Mol Cell Cardiol. 2005; 39: 537–544.[CrossRef][Medline] [Order article via Infotrieve]
46. Genet S, Kale RK, Baquer NZ. Effects of free radicals on cytosolic creatine kinase activities and protection by antioxidant enzymes and sulfhydryl compounds. Mol Cell Biochem. 2000; 210: 23–28.[CrossRef][Medline] [Order article via Infotrieve]
47. Komuro I, Yazaki Y. Control of cardiac gene expression by mechanical stress. Annu Rev Physiol. 1993; 55: 55–75.[CrossRef][Medline] [Order article via Infotrieve]
48. Hajjar RJ, del Monte F, Matsui T, Rosenzweig A. Prospects for gene therapy for heart failure. Circ Res. 2000; 86: 616–621.
49. Kambara A, Holycross BJ, Wung P, Schanbacher B, Ghosh S, McCune SA, Bauer JA, Kwiatkowski P. Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure. J Cardiovasc Pharmacol. 2003; 41: 830–837.[CrossRef][Medline] [Order article via Infotrieve]
50. McNally JS, Davis ME, Giddens DP, Saha A, Hwang J, Dikalov S, Jo H, Harrison DG. Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress. Am J Physiol Heart Circ Physiol. 2003; 285: H2290–H2297.
51. Maytin M, Siwik DA, Ito M, Xiao L, Sawyer DB, Liao R, Colucci WS. Pressure overload-induced myocardial hypertrophy in mice does not require gp91phox. Circulation. 2004; 109: 1168–1171.
Related Article:
Circ. Res. 2006 98: 169-171.
This article has been cited by other articles:
 |
|
 |
|
  E. Bartha, I. Solti, L. Kereskai, J. Lantos, E. Plozer, K. Magyar, E. Szabados, T. Kalai, K. Hideg, R. Halmosi, et al. PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats Cardiovasc Res, August 1, 2009; 83(3): 501 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Maloyan, H. Osinska, J. Lammerding, R. T. Lee, O. H. Cingolani, D. A. Kass, J. N. Lorenz, and J. Robbins Biochemical and Mechanical Dysfunction in a Mouse Model of Desmin-Related Myopathy Circ. Res., April 24, 2009; 104(8): 1021 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Xiao, Q. She, Y. Wang, K. Luo, Y. Yin, R. Hu, and K. Huang Effect of allopurinol on cardiomyocyte apoptosis in rats after myocardial infarction Eur J Heart Fail, January 1, 2009; 11(1): 20 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Garciarena, C. I. Caldiz, M. V. Correa, G. R. Schinella, S. M. Mosca, G. E. Chiappe de Cingolani, H. E. Cingolani, and I. L. Ennis Na+/H+ exchanger-1 inhibitors decrease myocardial superoxide production via direct mitochondrial action J Appl Physiol, December 1, 2008; 105(6): 1706 - 1713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Poornima, S. B. Brown, S. Bhashyam, P. Parikh, H. Bolukoglu, and R. P. Shannon Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure-Prone Rat Circ Heart Fail, September 1, 2008; 1(3): 153 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Hare, B. Mangal, J. Brown, C. Fisher Jr, R. Freudenberger, W. S. Colucci, D. L. Mann, P. Liu, M. M. Givertz, R. P. Schwarz, et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2301 - 2309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Boueiz, M. Damarla, and P. M. Hassoun Xanthine oxidoreductase in respiratory and cardiovascular disorders Am J Physiol Lung Cell Mol Physiol, May 1, 2008; 294(5): L830 - L840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Chicco, S. A. McCune, C. A. Emter, G. C. Sparagna, M. L. Rees, D. A. Bolden, K. D. Marshall, R. C. Murphy, and R. L. Moore Low-Intensity Exercise Training Delays Heart Failure and Improves Survival in Female Hypertensive Heart Failure Rats Hypertension, April 1, 2008; 51(4): 1096 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Kohr, H. Wang, D. G. Wheeler, M. Velayutham, J. L. Zweier, and M. T. Ziolo Targeting of phospholamban by peroxynitrite decreases {beta}-adrenergic stimulation in cardiomyocytes Cardiovasc Res, January 15, 2008; 77(2): 353 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Yamamoto, K. Kataoka, T. Yamashita, Y. Tokutomi, Y.-F. Dong, S. Matsuba, H. Ogawa, and S. Kim-Mitsuyama Role of Xanthine Oxidoreductase in the Reversal of Diastolic Heart Failure by Candesartan in the Salt-Sensitive Hypertensive Rat Hypertension, October 1, 2007; 50(4): 657 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Funakoshi, L. C. Zacharia, Z. Tang, J. Zhang, L. L. Lee, J. C. Good, D. E. Herrmann, Y. Higuchi, W. J. Koch, E. K. Jackson, et al. A1 Adenosine Receptor Upregulation Accompanies Decreasing Myocardial Adenosine Levels in Mice With Left Ventricular Dysfunction Circulation, May 1, 2007; 115(17): 2307 - 2315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Doerries, K. Grote, D. Hilfiker-Kleiner, M. Luchtefeld, A. Schaefer, S. M. Holland, S. Sorrentino, C. Manes, B. Schieffer, H. Drexler, et al. Critical Role of the NAD(P)H Oxidase Subunit p47phox for Left Ventricular Remodeling/Dysfunction and Survival After Myocardial Infarction Circ. Res., March 30, 2007; 100(6): 894 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Saliaris, L. C. Amado, K. M. Minhas, K. H. Schuleri, S. Lehrke, M. St. John, T. Fitton, C. Barreiro, C. Berry, M. Zheng, et al. Chronic allopurinol administration ameliorates maladaptive alterations in Ca2+ cycling proteins and beta-adrenergic hyporesponsiveness in heart failure Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1328 - H1335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Takimoto and D. A. Kass Role of Oxidative Stress in Cardiac Hypertrophy and Remodeling Hypertension, February 1, 2007; 49(2): 241 - 248. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Casadei The emerging role of neuronal nitric oxide synthase in the regulation of myocardial function Exp Physiol, November 1, 2006; 91(6): 943 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Zimmet and J. M. Hare Nitroso-Redox Interactions in the Cardiovascular System Circulation, October 3, 2006; 114(14): 1531 - 1544. [Full Text] [PDF]
|
|
|
|
|
|
B. J. Biesiadecki and R. J. Solaro When Hearts Fail So Does Skeletal Muscle: Breaking a Vicious Cycle Circ. Res., June 23, 2006; 98(12): 1456 - 1458. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Hajjar and J. A. Leopold Xanthine Oxidase Inhibition and Heart Failure: Novel Therapeutic Strategy for Ventricular Dysfunction? Circ. Res., February 3, 2006; 98(2): 169 - 171. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||